Back to video list Back to Home REAP-ing The Benefits In Clinical Practice: Eptinezumab – The Only CGRP Monoclonal Antibody With Real World Data In Asian Patients You may also like Migraine Satellite symposium Article New real-world data on the use of calcitonin gene-related peptide monoclonal antibodies for migraine prevention Schizophrenia Article Improving long-term outcomes in schizophrenia — translating evidence into practice Depression Article Assessing cognition in depression Schizophrenia Congress highlights Article Patients at high risk for psychosis pose a clinical dilemma